Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Sponsor: NSABP Foundation Inc
A observational or N/A phase clinical study on Breast Cancer and Depression, this trial is ongoing. The trial is conducted by NSABP Foundation Inc and has accumulated 13 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Jan 2026 — Present [monthly]
Unknown
-
Sep 2025 — Jan 2026 [monthly]
Unknown
-
Sep 2024 — Sep 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2021 — Jul 2024 [monthly]
Unknown Status
▶ Show 8 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Unknown Status
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
-
Jun 2018 — Nov 2020 [monthly]
Unknown Status
-
May 2018 — Jun 2018 [monthly]
Unknown Status
-
Apr 2018 — May 2018 [monthly]
Unknown Status
Phase: NA → None
-
Oct 2017 — Apr 2018 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Aug 2017 — Oct 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Active Not Recruiting NA
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NSABP Foundation Inc
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .